Charles Schwab
ARQT icon

Charles Schwab’s Arcutis Biotherapeutics ARQT Stock Holding History

Charles Schwab’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.6M Buy
1,050,934
+38,379
+4% +$894K ﹤0.01% 1634
2026
Q1 		$23.9M Sell
1,012,555
-2,271
-0.2% -$58K ﹤0.01% 1642
2025
Q4 		$29.5M Buy
1,014,826
+15,392
+2% +$394K ﹤0.01% 1505
2025
Q3 		$18.8M Buy
999,434
+34,368
+4% +$542K ﹤0.01% 1770
2025
Q2 		$13.5M Buy
965,066
+104,298
+12% +$1.46M ﹤0.01% 1863
2025
Q1 		$13.5M Sell
860,768
-18,036
-2% -$254K ﹤0.01% 1820
2024
Q4 		$12.2M Buy
878,804
+18,958
+2% +$208K ﹤0.01% 1927
2024
Q3 		$8M Buy
859,846
+8,522
+1% +$84.1K ﹤0.01% 2142
2024
Q2 		$7.92M Buy
851,324
+100,600
+13% +$910K ﹤0.01% 2152
2024
Q1 		$7.44M Buy
750,724
+179,406
+31% +$1.34M ﹤0.01% 2133
2023
Q4 		$1.85M Buy
571,318
+187,505
+49% +$510K ﹤0.01% 2645
2023
Q3 		$2.04M Buy
383,813
+53,871
+16% +$458K ﹤0.01% 2593
2023
Q2 		$3.14M Buy
329,942
+27,440
+9% +$305K ﹤0.01% 2413
2023
Q1 		$3.33M Buy
302,502
+774
+0.3% +$11.2K ﹤0.01% 2372
2022
Q4 		$4.47M Buy
301,728
+10,635
+4% +$186K ﹤0.01% 2272
2022
Q3 		$5.56M Buy
291,093
+73,833
+34% +$1.67M ﹤0.01% 2161
2022
Q2 		$4.63M Buy
217,260
+16,296
+8% +$334K ﹤0.01% 2216
2022
Q1 		$3.87M Buy
200,964
+2,511
+1% +$42.5K ﹤0.01% 2395
2021
Q4 		$4.12M Buy
198,453
+2,616
+1% +$52.1K ﹤0.01% 2445
2021
Q3 		$4.68M Buy
195,837
+2,455
+1% +$56K ﹤0.01% 2410
2021
Q2 		$5.28M Buy
193,382
+13,702
+8% +$386K ﹤0.01% 2324
2021
Q1 		$5.2M Buy
179,680
+38,241
+27% +$1.19M ﹤0.01% 2284
2020
Q4 		$3.98M Buy
141,439
+30,816
+28% +$755K ﹤0.01% 2333
2020
Q3 		$3.24M Buy
110,623
+42,377
+62% +$1.13M ﹤0.01% 2296
2020
Q2 		$2.06M Buy
68,246
+46,225
+210% +$1.34M ﹤0.01% 2415
2020
Q1 		$657K Buy
+22,021
New +$592K ﹤0.01% 2614

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Charles Schwab's ARQT Position: Q2 2026 in Review

Charles Schwab increased its Arcutis Biotherapeutics (ARQT) stake by 3.8% in Q2 2026, buying an estimated $894K and bringing the position to 1,050,934 shares worth $27.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1634.

Charles Schwab first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $29.5M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Charles Schwab held 1,050,934 shares of Arcutis Biotherapeutics worth $27.6M as of Q2 2026.
  • Charles Schwab bought 38,379 Arcutis Biotherapeutics shares in Q2 2026, an estimated $894K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1634 holding.
  • Charles Schwab first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • Charles Schwab's Arcutis Biotherapeutics position peaked at $29.5M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.